GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » ROC (Joel Greenblatt) %

ALNY (Alnylam Pharmaceuticals) ROC (Joel Greenblatt) % : -41.89% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Alnylam Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -41.89%.

The historical rank and industry rank for Alnylam Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1194.74   Med: -242.91   Max: -26.01
Current: -26.01

During the past 13 years, Alnylam Pharmaceuticals's highest ROC (Joel Greenblatt) % was -26.01%. The lowest was -1194.74%. And the median was -242.91%.

ALNY's ROC (Joel Greenblatt) % is ranked better than
74.89% of 1410 companies
in the Biotechnology industry
Industry Median: -307.695 vs ALNY: -26.01

Alnylam Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 26.80% per year.


Alnylam Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Alnylam Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals ROC (Joel Greenblatt) % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -183.09 -113.99 -98.48 -131.91 -42.65

Alnylam Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.16 -58.48 -15.69 12.32 -41.89

Competitive Comparison of Alnylam Pharmaceuticals's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Alnylam Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



Alnylam Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(309.481 + 83.981 + 154.745) - (882.623 + 69.009 + 61.963)
=-465.388

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(353.852 + 75.987 + 145.35) - (1016.973 + 71.03 + 90.516)
=-603.33

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Alnylam Pharmaceuticals for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-297.148/( ( (715.462 + max(-465.388, 0)) + (703.405 + max(-603.33, 0)) )/ 2 )
=-297.148/( ( 715.462 + 703.405 )/ 2 )
=-297.148/709.4335
=-41.89 %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alnylam Pharmaceuticals  (NAS:ALNY) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Alnylam Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals Business Description

Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Executives
Tolga Tanguler officer: EVP, Chief Commercial Officer 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Yvonne Greenstreet officer: EVP, Chief Commercial Officer PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton officer: Chief Financial Officer 300 THIRD STREET, CAMBRIDGE MA 02142
Pushkal Garg officer: CMO & EVP Dev & Med Affairs C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Dennis A Ausiello director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Amy W Schulman director PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Phillip A Sharp director BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Indrani Lall Franchini officer: EVP, CLO & Secretary C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Michael W Bonney director 65 HAYDEN AVE, LEXINGTON MA 02421
Akshay Vaishnaw officer: SVP, Clinical Research 300 THIRD STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
John Maraganore director, officer: President and CEO 75 SIDNEY ST, CAMBRIDGE MA 02139

Alnylam Pharmaceuticals Headlines